dMMR/MSI-H rectal cancer | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

116,525 results for “dMMR/MSI-H rectal cancer”

Trials

View all 95985 →

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

47 participants · First posted Nov 24, 2020

Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

6 participants · First posted Apr 22, 2020

Active, not recruiting

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

154 participants · First posted Feb 10, 2023

Drugs

View all 3302 →

Colorectal cancer vaccine (Oryx)

Yinhu Rectal Gelatum

Methoxamine rectal (Norgine)

Organizations

View all 1406 →

H LEE MOFFITT CANCER CENTER

United States

H LEE MOFFITT CANCER CENTER AND RESEARCH

United States

MSI ASIA PACIFIC

Australia

News

View all 15832 →

FDA Grants Breakthrough Therapy Designation to GSK's Jemperli for Advanced Rectal Cancer

GSK's Cancer Portfolio Gains Momentum with Regulatory Successes for Dostarlimab and GSK'227

AnaptysBio Plans Corporate Split to Separate Royalty Assets from Drug Development Operations

Page 1 of 11653